Početna stranicaAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
9,01 $
Poslije radnog vremena:(0,00 %)0,00
9,01 $
Zatvoreno: 16. svi, 20:00:00 GMT -4 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
8,89 $
Dnevni raspon
8,69 $ - 9,02 $
Godišnji raspon
6,38 $ - 17,30 $
Tržišna kapitalizacija
871,62 mil. USD
Prosječna količina
1,33 mil.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ožu 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 52,51 mil. | 93,21 % |
Operativni troškovi | 49,94 mil. | −3,40 % |
Neto dohodak | −4,92 mil. | 82,01 % |
Neto profitabilnost | −9,37 | 90,69 % |
Zarada po dionici | −0,05 | 83,33 % |
EBITDA | −2,18 mil. | 91,46 % |
Efektivna porezna stopa | −1,61 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ožu 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 66,48 mil. | −25,12 % |
Ukupna imovina | 167,95 mil. | 0,03 % |
Ukupne obveze | 93,88 mil. | 4,88 % |
Ukupni kapital | 74,07 mil. | — |
Dionice u optjecaju | 96,74 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 11,55 | — |
Povrat imovine | −4,52 % | — |
Povrat kapitala | −6,61 % | — |
Tok novca
Neto promjena novca
| (USD) | ožu 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −4,92 mil. | 82,01 % |
Gotovina od poslovanja | −8,23 mil. | 72,29 % |
Gotovina iz ulaganja | 12,32 mil. | −42,41 % |
Gotovina iz financiranja | 690,00 tis. | −94,77 % |
Neto promjena novca | 5,00 mil. | 8,04 % |
Slobodan tok novca | −8,71 mil. | 55,25 % |
Više
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Glavni izvršni direktor
Osnovano
1990
Web-lokacija
Zaposlenici
188
